CombiMatrix Corp (CBMX)

6.25
0.20 3.18
NASDAQ : Health Care
Prev Close 6.46
Open 6.55
Day Low/High 6.11 / 6.60
52 Wk Low/High 2.20 / 8.20
Volume 51.82K
Avg Volume 45.60K
Exchange NASDAQ
Shares Outstanding 2.94M
Market Cap 18.40M
EPS -3.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CombiMatrix Notes Decision By Health Care Service Corporation To Reimburse For Recurrent Pregnancy Loss Testing

CombiMatrix Notes Decision By Health Care Service Corporation To Reimburse For Recurrent Pregnancy Loss Testing

Trend continues by health providers to cover chromosomal microarray testing for recurrent pregnancy loss

CombiMatrix Announces Distribution Agreement With Universal Diagnostic Laboratories For Miscarriage Analysis Testing

CombiMatrix Announces Distribution Agreement With Universal Diagnostic Laboratories For Miscarriage Analysis Testing

Agreement expands access to CombiMatrix's test for women in the state of California

CombiMatrix Study Published In Genetics In Medicine Establishes The Superior Diagnostic Value Of Microarray Analysis Over Karyotyping For Recurrent Pregnancy Loss Testing

CombiMatrix Study Published In Genetics In Medicine Establishes The Superior Diagnostic Value Of Microarray Analysis Over Karyotyping For Recurrent Pregnancy Loss Testing

Data further validates CombiMatrix's microarray testing for miscarriage analysis and supports position as commercial and scientific leader in the $300 million annual U.S. market

CombiMatrix Launches Next Generation Sequencing For Pre-Implementation Genetic Screening

CombiMatrix Launches Next Generation Sequencing For Pre-Implementation Genetic Screening

High sensitivity and specificity PGS testing by Next Generation Sequencing supports healthy pregnancies and builds on prenatal diagnostics portfolio

CombiMatrix Comments On Additional Medical Policy Revisions To Reimburse For Recurrent Pregnancy Loss Testing

CombiMatrix Comments On Additional Medical Policy Revisions To Reimburse For Recurrent Pregnancy Loss Testing

Genetic testing now categorized by six additional health plans as medically necessary for the evaluation of pregnancy loss in specific cases